Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Piotr Centkowski"'
Autor:
Szymon Skoczen, Konrad Stepien, Wojciech Mlynarski, Piotr Centkowski, Kinga Kwiecinska, Michal Korostynski, Marcin Piechota, Elzbieta Wyrobek, Angelina Moryl-Bujakowska, Wojciech Strojny, Magdalena Rej, Jerzy Kowalczyk, Walentyna Balwierz
Publikováno v:
Frontiers in Oncology, Vol 9 (2020)
The aim of the following case report is to provide a description of acute lymphoblastic leukemia (ALL) in a patient with Netherton syndrome (NS). A 15-year-old male with NS was referred with suspicion of acute leukemia. Severe anemia, leukocytosis, t
Externí odkaz:
https://doaj.org/article/1c46eee17c2745e4860b42f87b7f8f70
Autor:
Katarzyna Kapelko-Słowik, Magdalena Czemerska, Piotr Centkowski, Anna Waszczuk-Gajda, Sara Zawadzka-Leska, Wioletta Makowska, Rafał Machowicz, Aleksandra Gołos, Jadwiga Hołojda, Patrycja Rusicka, Grzegorz W. Basak, Edyta Subocz, Karol Lis, Anna Masternak, Bartłomiej Pogłódek, Joanna Drozd-Sokołowska, Tomasz Czerw, Elżbieta Wiater, Andrzej Tukiendorf, Jadwiga Dwilewicz-Trojaczek, Anna Kopińska, Krzysztof Mądry, Janusz Hałka, Paweł Szwedyk
Publikováno v:
Hematology (Amsterdam, Netherlands). 26(1)
Azacitidine (AZA) is the standard of care for higher-risk myelodysplastic syndrome (HR-MDS) patients ineligible for intensive therapy. Clinical outcome discrepancies reported in clinical trials and real-life settings stimulate the search for new prog
Autor:
Matias Rodrigo Chacon, Hernan J. Cutuli, Sergio Bracarda, Marco Maruzzo, Maria Teresa Bourlon, Carmel Jacobs, Begoña Pérez-Valderrama, Ignacio Magri, Martin Richardet, Piotr Centkowski, Simon Yuen Fai Fu, Pablo Gurman, Srivani Konduri, Zhuoxin Yu, Heather Vezina, Saby George, Laurence Albiges
Publikováno v:
Journal of Clinical Oncology. 40:TPS4621-TPS4621
TPS4621 Background: Nivolumab (NIVO), a programmed death-1 immune checkpoint inhibitor, has demonstrated clinical efficacy across patients with different tumor types, including clear cell renal cell carcinoma (ccRCC), when administered via IV infusio
Autor:
Marta Macioch, Piotr Centkowski
Publikováno v:
Oncology in Clinical Practice. 14:232-236
A case of a 34-year-old male patient was described with increased sweating, itching of the skin without accompanying skin lesions, and a dry cough. Numerous enlarged nodes in the chest and hypodense centres in the spleen were visualised in the CT ima
Autor:
Piotr, Centkowski, Eve, Chowaniec, Krzysztof, Okoń, Dariusz, Adamek, Marek, Kuźniewski, Katarzyna, Krzanowska
Publikováno v:
Polish archives of internal medicine. 130(1)
Autor:
Dariusz Adamek, Eve Chowaniec, Krzysztof Okoń, Piotr Centkowski, Katarzyna Krzanowska, Marek Kuźniewski
Publikováno v:
Polish Archives of Internal Medicine.
Autor:
Anna Waszczuk-Gajda, Grzegorz W. Basak, Sara Zawadzka-Leska, Jadwiga Dwilewicz-Trojaczek, Paweł Szwedyk, Anna Masternak, Hołojda Jadwiga, Bartłomiej Pogłódek, Wiater Elżbieta, Patrycja Rusicka, Magdalena Czemerska, Andrzej Tukiendorf, Aleksandra Gołos, Krzysztof Madry, Wioletta Makowska, Anna Kopińska, Piotr Centkowski, Rafał Machowicz, Katarzyna Kapelko-Słowik, Karol Lis, Janusz Hałka, Edyta Subocz, Joanna Drozd-Sokołowska
Publikováno v:
Blood. 134:5421-5421
Background: Azacitidine is the current standard of care for higher risk MDS patients (HR MDS) changing the natural course of diseases. Early drug discontinuation (receiving less than 4 azacitidine cycles - early failure - EF) is a poor prognostic mar
Autor:
Joanna Sawczuk-Chabin, Elżbieta Kisiel, Wojciech Jurczak, Wanda Knopinska-Posluszny, Piotr Centkowski, Omeir Khan
Publikováno v:
Contemporary Oncology
Aim of the study To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in the management of DLBCL. Material and methods Patients with primary refractory or high-risk DLBCL (n = 18), ineligible fo
Autor:
Rutkowska Elżbieta, Maria Król, Paulina Wlasiuk, Adrian Burdacki, Tomasz Wróbel, Anna Waszczuk-Gajda, Agnieszka Druzd-Sitek, Dominik Dytfeld, Krzysztof Jamroziak, Krzysztof Lewandowski, Iwona Solarska, Agnieszka Krzywdzińska, Artur Jurczyszyn, Krzysztof Warzocha, Pawel Bernatowicz, Piotr Centkowski, Olga Jankowska-Łęcka, Jan Maciej Zaucha, Krzysztof Giannopoulos, Agata Tyczyńska, Bartosz Pula, Donata Szymczak, Anna Czyż, Agnieszka Balana-Nowak, Alina Świderska, Marek Dudziński
Studies exploring the significance of minimal residual disease (MRD) in plasma cell myeloma (PCM) have proven its prognostic value, regardless of the type of administered treatment. In order to assess the current practice for evaluating MRD in Poland
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00fd050681070f95720d83c855f7a2a6
https://ruj.uj.edu.pl/xmlui/handle/item/108699
https://ruj.uj.edu.pl/xmlui/handle/item/108699
Autor:
Irena Federowicz, Ewa Kalinka-Warzocha, Lidia B. Brydak, Przemysław Biliński, Ewa Lech-Marańda, Joanna Sawczuk-Chabin, Dariusz Wołowiec, Magdalena Machała, Piotr Centkowski, Jan Walewski, Joanna Wegrzyn, Krzysztof Warzocha, Maria Błasińska-Morawiec
Publikováno v:
Journal of Clinical Immunology. 27:339-346
Purpose: The purpose of this study was to assess humoral response to influenza vaccine in patients (pts) with non-Hodgkin lymphoma (NHL) as compared to healthy subjects (ctrl). Patients and methods: In two epidemic seasons, 2003/2004 and 2004/2005, 1